March 26, 2018
Stockholm – March 26th, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that it has broaden its management team with the appointment of Dr Christian Jacques as Executive Vice President Clinical Strategy and Chief Scientific Officer (CSO). Dr Jacques has more than 25 years of experience in clinical development of new chemical entity’s within hematology-oncology leading to approval of several innovative pharmaceuticals in oncology and hematology, including pomalidomide.
“The appointment of Dr Christian Jacques as EVP Clinical Strategy and Chief Scientific Officer is an important step in building the Oncopeptides organization. Dr Jacques will be leading the regulatory submission team for Ygalo® globally as well as mapping out the clinical development strategy for both Ygalo® and our pipeline candidates. Dr Jacques is one of the most experienced senior developers in multiple myeloma and hematology globally. It is a privilege to welcome him to the Oncopeptides management team. " said Jakob Lindberg, CEO of Oncopeptides.
Bio - Dr Christians Jacques, MD
Dr Christians Jacques is a MD in Internal Medicine with specialization in Hematology-Oncology. His previous positions include global Myeloma Therapeutic Area Head at Celgene Inc, Executive Director at Novartis Oncology, Global Senior Director Oncology at Johnson and Johnson and various positions at Aventis, Rhone-Poulenc and Pierre Fabre all in the field of oncology. Dr Jacques is also a member of the American Society of Hematology and a member of the American Society of Clinical Oncology.
For further information, please contact:
Jakob Lindberg, CEO of Oncopeptides
Cell phone: : +46 705 695 471
Rein Piir, Head of Investor Relations at Oncopeptides
Cell phone. +46 708 537 292
The information was submitted through the agency of the contact person above for publication at 08.00 CET on March 26, 2018.
Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. The company focus on the development of the lead product candidate Ygalo®, an innovative, Peptidase Enhanced Cytotoxics (PEnCs). Ygalo® is intended for an effective treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program is intended to demonstrate better results from treatment with Ygalo® compared to established alternative drugs for patients with late-stage multiple myeloma. Ygalo® could potentially provide physicians with a new treatment option for patients suffering from this serious disease.
For more information. Visit www.oncopeptides.se